Health TidingsTempest Advances TPST-4003 Toward First Clinical Evaluation of In Vivo CAR-... Tempest Advances TPST-4003 Toward First Clinical Evaluation of In Vivo CAR-... Read Post »
Health TidingsIMUNON Reports Positive Phase 2 Translational Data Supporting IMNN-001 in A... IMUNON Reports Positive Phase 2 Translational Data Supporting IMNN-001 in A... Read Post »
Medical DevicesEnvoy Medical Completes Three-Month Milestone in Acclaim Cochlear Implant T... Envoy Medical Completes Three-Month Milestone in Acclaim Cochlear Implant T... Read Post »
Health TidingsNOUS-209 Re-Treatment Boosts Durable T-Cell Responses in Lynch Syndrome NOUS-209 Re-Treatment Boosts Durable T-Cell Responses in Lynch Syndrome Read Post »
Health TidingsPhanes Advances Spevatamig-KYTRUDA in First-Line Biliary Tract Cancer with ... Phanes Advances Spevatamig-KYTRUDA in First-Line Biliary Tract Cancer with ... Read Post »
Health TidingsFDA Grants Fast Track Designation to Oncolytics’s Pelareorep FDA Grants Fast Track Designation to Oncolytics’s Pelareorep Read Post »
Health Tidings Mergers & AcquisitionsHalozyme and Incyte Partner to Advance Subcutaneous INCA033989 for mutCALR-... Halozyme and Incyte Partner to Advance Subcutaneous INCA033989 for mutCALR-... Read Post »
Health TidingsFDA Grants Priority Review to Dyne’s z-Rostudirsen for DMD FDA Grants Priority Review to Dyne’s z-Rostudirsen for DMD Read Post »
Health TidingsNamodenoson Shows Durable Disease Control in Advanced Pancreatic Cancer Namodenoson Shows Durable Disease Control in Advanced Pancreatic Cancer Read Post »
Health TidingsDuvakitug Improves Clinical Remission in Ulcerative Colitis Trial Duvakitug Improves Clinical Remission in Ulcerative Colitis Trial Read Post »
Health TidingsSafusidenib Delivers Long-Term Benefit in Grade 2 IDH1-Mutant Glioma Safusidenib Delivers Long-Term Benefit in Grade 2 IDH1-Mutant Glioma Read Post »
Health TidingsDuvakitug Shows Positive Phase 2b Results in Crohn’s Disease Duvakitug Shows Positive Phase 2b Results in Crohn’s Disease Read Post »
Health TidingsEMA Accepts GSK’s Bexsero Single-Dose Booster Label Expansion EMA Accepts GSK’s Bexsero Single-Dose Booster Label Expansion Read Post »
Health TidingsPivotal Bexicaserin Trial Completes Randomization in Rare Childhood Epileps... Pivotal Bexicaserin Trial Completes Randomization in Rare Childhood Epileps... Read Post »
GenericsNATCO Pharma Secures Tentative US FDA Approval for Generic Olaparib Tablets NATCO Pharma Secures Tentative US FDA Approval for Generic Olaparib Tablets Read Post »
Health TidingsKamuvudine-8 Reduced Geographic Atrophy Progression by 54% in Phase 2 Study Kamuvudine-8 Reduced Geographic Atrophy Progression by 54% in Phase 2 Study Read Post »
Health TidingsInnoCare’s Soficitinib Meets Phase II Endpoint in Vitiligo InnoCare’s Soficitinib Meets Phase II Endpoint in Vitiligo Read Post »
GenericsAmneal Secures FDA Approval for Additional Iohexol Injection Presentations,... Amneal Secures FDA Approval for Additional Iohexol Injection Presentations,... Read Post »
Health TidingsCamurus CAM2029 NDA Accepted by FDA for Acromegaly Camurus CAM2029 NDA Accepted by FDA for Acromegaly Read Post »
Health TidingsShionogi’s Fetroja sNDA Accepted by FDA for Pediatric Hospital Pneumonia ... Shionogi’s Fetroja sNDA Accepted by FDA for Pediatric Hospital Pneumonia ... Read Post »
Health TidingsFabhalta Secures Full FDA Approval to Slow Kidney Function Decline in IgA N... Fabhalta Secures Full FDA Approval to Slow Kidney Function Decline in IgA N... Read Post »
Health TidingsDimerix Acquires Phase 2-Ready DMX-652 for Acute Kidney Injury Dimerix Acquires Phase 2-Ready DMX-652 for Acute Kidney Injury Read Post »
Health TidingsTrellis Raises $9M to Advance Calpurbatug Phase 2 in Prosthetic Joint Infec... Trellis Raises $9M to Advance Calpurbatug Phase 2 in Prosthetic Joint Infec... Read Post »
Health TidingsMedicus Advances Optimized Phase 2 Teverelix Trial After FDA Feedback Medicus Advances Optimized Phase 2 Teverelix Trial After FDA Feedback Read Post »
Health TidingsKalshi and AppliedXL Launch Prediction Markets for Clinical Trial Outcomes Kalshi and AppliedXL Launch Prediction Markets for Clinical Trial Outcomes Read Post »
ManufacturingGates MRI Taps GSK’s AS01E Adjuvant and Serum Institute of India̵... Gates MRI Taps GSK’s AS01E Adjuvant and Serum Institute of India̵... Read Post »
Health TidingsCOMP360 Phase 2 Analysis Supports Psilocybin Effects in PTSD COMP360 Phase 2 Analysis Supports Psilocybin Effects in PTSD Read Post »
Health Tidings Mergers & AcquisitionsChai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody ... Chai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody ... Read Post »
Health Tidings Mergers & AcquisitionsLilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant Depre... Lilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant Depre... Read Post »
Health TidingsEisai’s Lemborexant Marketing Application Accepted by EMA for Chronic Ins... Eisai’s Lemborexant Marketing Application Accepted by EMA for Chronic Ins... Read Post »
Health TidingsAxsome’s AXS-12 NDA for Narcolepsy Cataplexy Accepted by FDA Axsome’s AXS-12 NDA for Narcolepsy Cataplexy Accepted by FDA Read Post »
Health TidingsVeradermics’ Oral VDPHL01 Shows Strong Hair Growth in Phase 2 Study o... Veradermics’ Oral VDPHL01 Shows Strong Hair Growth in Phase 2 Study o... Read Post »
Health TidingsRAG-17 Reduced SOD1 by 69% in Phase 1 Amyotrophic Lateral Sclerosis Trial RAG-17 Reduced SOD1 by 69% in Phase 1 Amyotrophic Lateral Sclerosis Trial Read Post »
Health TidingsOrelabrutinib Significantly Improves Progression-Free Survival as First-Lin... Orelabrutinib Significantly Improves Progression-Free Survival as First-Lin... Read Post »
Health TidingsApnimed’s AD109 NDA Accepted by FDA for Obstructive Sleep Apnea Apnimed’s AD109 NDA Accepted by FDA for Obstructive Sleep Apnea Read Post »
Health TidingsFDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Pri... FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Pri... Read Post »
GenericsFDA Approves First Generic Afatinib Tablets for EGFR-Mutated NSCLC FDA Approves First Generic Afatinib Tablets for EGFR-Mutated NSCLC Read Post »
Health Tidings Regulatory & Health PolicyFDA Releases First Psychedelic Drug Development Guidance FDA Releases First Psychedelic Drug Development Guidance Read Post »
Health TidingsSummit Sells Phase III Antibiotic Ridinilazole to Biossil in Up to $105 Mil... Summit Sells Phase III Antibiotic Ridinilazole to Biossil in Up to $105 Mil... Read Post »
Health Tidings Mergers & AcquisitionsNovartis Partners With Chai Discovery to Advance AI Antibody Discovery Novartis Partners With Chai Discovery to Advance AI Antibody Discovery Read Post »
Health Tidings Mergers & AcquisitionsSpero Secures Global Rights to Innovent’s Anti-CD40L Antibody IBI355 in U... Spero Secures Global Rights to Innovent’s Anti-CD40L Antibody IBI355 in U... Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca Licenses Zegfrovy from Dizal in Up to $1.5 Billion Deal to Expa... AstraZeneca Licenses Zegfrovy from Dizal in Up to $1.5 Billion Deal to Expa... Read Post »
Health Tidings Mergers & AcquisitionsIndonesia Grants Takeda Plasma Fractionation License for PDMP Production Indonesia Grants Takeda Plasma Fractionation License for PDMP Production Read Post »
Health TidingsAgenus Secures $340M to Advance ROBBIN Trial of Botensilimab + Balstilimab ... Agenus Secures $340M to Advance ROBBIN Trial of Botensilimab + Balstilimab ... Read Post »
Health TidingsArmata Receives FDA Agreement on Pediatric Study Plan for AP-SA02 Armata Receives FDA Agreement on Pediatric Study Plan for AP-SA02 Read Post »
Health TidingsBioMarin’s VOXZOGO sNDA Accepted by FDA for Full Approval in Children wit... BioMarin’s VOXZOGO sNDA Accepted by FDA for Full Approval in Children wit... Read Post »
Health TidingsIpsen Reports Positive Phase IIIb Results for IQIRVO in PBC Ipsen Reports Positive Phase IIIb Results for IQIRVO in PBC Read Post »
Health TidingsLongeveron Reports New Phase 2a Data Showing Laromestrocel Reduced Brain In... Longeveron Reports New Phase 2a Data Showing Laromestrocel Reduced Brain In... Read Post »
Health TidingsLatarcibart Reduces Annual Bleeding Rate by 81% in Phase 1/2 Study of Von W... Latarcibart Reduces Annual Bleeding Rate by 81% in Phase 1/2 Study of Von W... Read Post »
Health TidingsLongBio Pharma Wins FDA IND Clearance for LP-003 Peanut Allergy Trial LongBio Pharma Wins FDA IND Clearance for LP-003 Peanut Allergy Trial Read Post »
